ActiveMSers Forums  

Go Back   ActiveMSers Forums > ActiveMSers.org Forums > General

 
 
Thread Tools Display Modes
Prev Previous Post   Next Post Next
  #1  
Old 10-21-2019, 12:29 PM
ActiveMSers's Avatar
ActiveMSers ActiveMSers is online now
Dave @ ActiveMSers
 
Join Date: Jun 2008
Location: Albuquerque, NM
Posts: 3,831
Default Could HDL cholesterol influence MS disease progression?

The question is gaining traction. Exercise influences HDL cholesterol (the good kind). Diet can influence HDL. And new research shows that some MS drugs do, too:

HDL-cholesterol elevation associated with fingolimod and dimethyl fumarate therapies in multiple sclerosis

S Blumenfeld Kan, E Staun-Ram, D Golan, ...
First Published October 14, 2019

https://doi.org/10.1177/2055217319882720


Abstract

Background
Patients with Multiple Sclerosis (PwMS) display altered lipoproteins levels and function, which seem to affect disease risk and progress. Whether disease-modifying therapies affect the lipoprotein profile in PwMS has scarcely been studied.

Objective
The study aims to assess whether fingolimod and dimethyl fumarate (DMF) affect lipoproteins in PwMS.

Methods
We compared retrospectively the blood lipoprotein levels of 29 fingolimod-treated and 41 DMF-treated patients before and after 3 and 12 months of therapy. Patients treated with cholesterol-reducing medications were not included. Data on weight change and disease activity during 1-year follow-up were obtained.

Results
HDL level, HDL/LDL ratio and HDL/total cholesterol ratio were increased in both treatment groups after 3 months’ therapy and sustained, with no change in LDL or triglycerides. While at baseline only 26% of patients met the recommended minimum of HDL 60 mg/dl, after 3 months’ therapy, 43% of fingolimod-treated and 47% of DMF-treated patients reached the recommended level. The majority of patients had no weight reduction.

Conclusions
Fingolimod and DMF therapies are associated with a specific increase in HDL in PwMS. Further studies are required to validate these findings and their potential implication as biomarker of reduced inflammatory state and/or reduced risk of neurodegeneration or cardiovascular comorbidity.
__________________
Dave Bexfield
ActiveMSers
Reply With Quote
 

Thread Tools
Display Modes

Posting Rules
You may not post new threads
You may not post replies
You may not post attachments
You may not edit your posts

BB code is On
Smilies are On
[IMG] code is On
HTML code is Off
Forum Jump


All times are GMT -4. The time now is 04:55 PM.


Powered by vBulletin® Version 3.7.0
Copyright ©2000 - 2020, Jelsoft Enterprises Ltd.
ActiveMSers